303 related articles for article (PubMed ID: 15504160)
1. The use of recombinant activated factor VII in three patients with central nervous system hemorrhages associated with factor VII deficiency.
Huang WY; Kruskall MS; Bauer KA; Uhl L; Shaz BH
Transfusion; 2004 Nov; 44(11):1562-6. PubMed ID: 15504160
[TBL] [Abstract][Full Text] [Related]
2. Recombinant activated factor VII (rFVIIa) treatment in infants with hemorrhage.
Brady KM; Easley RB; Tobias JD
Paediatr Anaesth; 2006 Oct; 16(10):1042-6. PubMed ID: 16972833
[TBL] [Abstract][Full Text] [Related]
3. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
Santagostino E; Morfini M; Rocino A; Baudo F; Scaraggi FA; Gringeri A
Thromb Haemost; 2001 Oct; 86(4):954-8. PubMed ID: 11686352
[TBL] [Abstract][Full Text] [Related]
4. Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder.
Yilmaz D; Karapinar B; Balkan C; Akisü M; Kavakli K
Pediatr Hematol Oncol; 2008 Jun; 25(4):301-11. PubMed ID: 18484474
[TBL] [Abstract][Full Text] [Related]
5. A multicenter assessment of recombinant factor VIIa off-label usage: clinical experiences and associated outcomes.
MacLaren R; Weber LA; Brake H; Gardner MA; Tanzi M
Transfusion; 2005 Sep; 45(9):1434-42. PubMed ID: 16131375
[TBL] [Abstract][Full Text] [Related]
6. Levels of prothrombin activation peptide F1+2 in patients with a bleeding tendency.
Ingerslev J; Holm M; Christiansen K; Knudsen L; Négrier C
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S129-34. PubMed ID: 9819044
[TBL] [Abstract][Full Text] [Related]
7. Successful control of central nervous system bleeding in two newborns with severe factor VII deficiency using rFVIIa administered via Port-a-Cath.
Karimi M
Semin Hematol; 2008 Apr; 45(2 Suppl 1):S74. PubMed ID: 18544432
[TBL] [Abstract][Full Text] [Related]
8. Outcome of intracranial hemorrhage in infants with congenital factor VII deficiency.
Chuansumrit A; Visanuyothin N; Puapunwattana S; Chaivisuth A; Rasmidat P; Charoenkwan P; Chiemchanya S
J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1059-64. PubMed ID: 12549776
[TBL] [Abstract][Full Text] [Related]
9. Continuous infusion of recombinant factor VIIa for surgery in patients with deficiency of factor VII.
Schulman S; Tjønnfjord GE; Wallensten R; Martinowitz U; Kenet G
Thromb Haemost; 2005 Dec; 94(6):1177-80. PubMed ID: 16411390
[TBL] [Abstract][Full Text] [Related]
10. Treatment of massive cecal bleeding in a 28-Year-old patient with homozygous factor V deficiency with activated factor VII.
Petros S; Fischer J; Mössner J; Schiefke I; Teich N
Z Gastroenterol; 2008 Mar; 46(3):271-3. PubMed ID: 18322882
[TBL] [Abstract][Full Text] [Related]
11. Recombinant activated factor VII in cardiac surgery: experience from the Australian and New Zealand Haemostasis Registry.
Dunkley S; Phillips L; McCall P; Brereton J; Lindeman R; Jankelowitz G; Cameron P
Ann Thorac Surg; 2008 Mar; 85(3):836-44. PubMed ID: 18291152
[TBL] [Abstract][Full Text] [Related]
12. Recombinant activated factor VII: treating postoperative hemorrhage in cardiac surgery.
Bishop CV; Renwick WE; Hogan C; Haeusler M; Tuckfield A; Tatoulis J
Ann Thorac Surg; 2006 Mar; 81(3):875-9. PubMed ID: 16488687
[TBL] [Abstract][Full Text] [Related]
13. The use of recombinant activated factor VII in the circumcision operation in the case of a congenital factor VII deficiency.
Canatan D; Eren E; Ozgüner IF; Duman H; Eren C; Büyükyavuz I; Savaş C
Blood Coagul Fibrinolysis; 2007 Jun; 18(4):375-6. PubMed ID: 17473581
[TBL] [Abstract][Full Text] [Related]
14. Antigenicity of activated recombinant factor VII followed through nine years of clinical experience.
Nicolaisen EM
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S119-23. PubMed ID: 9819042
[TBL] [Abstract][Full Text] [Related]
15. Recombinant activated factor VIIa in uncontrolled bleeding: a haemostasis laboratory study in non-haemophilia patients.
Brandsborg S; Sørensen B; Poulsen LH; Ingerslev J
Blood Coagul Fibrinolysis; 2006 Jun; 17(4):241-9. PubMed ID: 16651865
[TBL] [Abstract][Full Text] [Related]
16. Recombinant activated factor VII as a universal haemostatic agent.
Hedner U
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S147-52. PubMed ID: 9819047
[TBL] [Abstract][Full Text] [Related]
17. [Clinical assessment of potential fields of application of recombinant factor VIIa in internal and pediatric diseases. Recommendations of an expert group].
Dempfle CE; Gulba D; Kirchmaier CM; Klamroth R; Korte W; Lorenz R; Peck-Radosavljevic M; Veldman A; Zotz RB
Med Klin (Munich); 2007 Jan; 102(1):70-81. PubMed ID: 17221356
[TBL] [Abstract][Full Text] [Related]
18. Prolonged prothrombin time after recombinant activated factor VII therapy in critically bleeding trauma patients is associated with adverse outcomes.
McMullin NR; Wade CE; Holcomb JB; Nielsen TG; Rossaint R; Riou B; Rizoli SB; Kluger Y; Choong PI; Warren B; Tortella BJ; Boffard KD;
J Trauma; 2010 Jul; 69(1):60-9. PubMed ID: 20622579
[TBL] [Abstract][Full Text] [Related]
19. Prevention of bleeding and hemorrhagic complications in surgical patients with inherited factor VII deficiency.
Wiszniewski A; Szczepanik A; Misiak A; Bykowska K; Szopiński P
Blood Coagul Fibrinolysis; 2015 Apr; 26(3):324-30. PubMed ID: 25688458
[TBL] [Abstract][Full Text] [Related]
20. Replacement therapy for bleeding episodes in factor VII deficiency. A prospective evaluation.
Mariani G; Napolitano M; Dolce A; Pérez Garrido R; Batorova A; Karimi M; Platokouki H; Auerswald G; Bertrand AM; Di Minno G; Schved JF; Bjerre J; Ingerslev J; Sørensen B; Ruiz-Saez A; ;
Thromb Haemost; 2013 Feb; 109(2):238-47. PubMed ID: 23238632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
